Moreover, systemic inhibition of VEGF-A or VEGF-B signaling by injecting neutralizing monoclonal antibodies have also shown remarkable effects in improving insulin sensitivity in the muscle, adipose tissue, and the liver of high-fat diet-induced mouse models of obesity and diabetes (Hagberg et al., 2012; Wu et al., 2014). The gene discussed is VEGFB; the disease is diabetes mellitus.